Format

Send to

Choose Destination
Future Oncol. 2019 May 8. doi: 10.2217/fon-2019-0031. [Epub ahead of print]

Nivolumab plus ipilimumab in non-small-cell lung cancer.

Author information

1
LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Woehrendamm 80, 22927 Grosshansdorf, Germany.
2
Division of Thoracic Medical Oncology, Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
3
Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, QLD 4102, Australia.

Abstract

Nivolumab and ipilimumab, two therapeutic immune checkpoint inhibitor antibodies that block PD-1 and CTLA-4, respectively, have indications in cancer as single agents and in combination. In this review, we examine the potential role of dual immune checkpoint inhibition with nivolumab plus ipilimumab in the management of patients with previously untreated advanced non-small-cell lung cancer, based on results from the Phase III CheckMate 227 study. Immunotherapies with indications in the first-line treatment of non-small-cell lung cancer include pembrolizumab alone and combined with chemotherapy, and atezolizumab combined with bevacizumab and chemotherapy. CheckMate 227 is the first Phase III study evaluating first-line chemotherapy-sparing combination immunotherapy and including tumor mutational burden as a biomarker for patient selection.

KEYWORDS:

CTLA-4; PD-1; PD-L1; atezolizumab; immunotherapy; ipilimumab; nivolumab; non-small-cell lung cancer; pembrolizumab; tumor mutational burden

PMID:
31066582
DOI:
10.2217/fon-2019-0031
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center